Clinical trial registry record

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase

A registered study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Withdrawn.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 19, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03791580
Last registry update
December 19, 2025
Status
Withdrawn
Phase
Phase not reported
Sponsor
RAND
Enrollment
0
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · FACTORIAL · HEALTH SERVICES RESEARCH · NONE
Evidence population
Human clinical study registration
Participants
0
Population
ALL · 18 Years
Duration
2019-02-01 to 2019-09-01
Intervention
Commitment nudge; Justification nudge
Comparator
Non-participating
Outcomes measured
High-risk polypharmacy criterion: Fall condition-drug interaction — 28 months; High-risk polypharmacy criterion: Fall drug-drug interaction — 28 month; High-risk polypharmacy criterion: CKD-glyburide/glimepiride interaction — 28 months; High-risk polypharmacy criterion: CKD-NSAID interaction — 28 months; High-risk polypharmacy criterion: CHF-NSAID interaction — 28 months; High-risk polypharmacy criterion: CHF-non-dihydropyridine calcium channel blocker interaction — 28 months; High-risk polypharmacy criterion: CHF-thiazolidinedione interaction — 28 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Polypharmacy · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

polypharmacy
Read the original source →Export JSON